Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024
Artificial Intelligence and Machine Learning in Clinical Medicine, 2023
NEjM 388:1201-1208,1220, Haug,C.H. & Drazen,J.M., 2023
Improving Neurology Clinical Care with Natural Language Processing Tools
Neurol 101:1010-1018, Ge,W.,et al, 2023
Large Language Models in Neurology Research and Future Practice
Neurol 101:1058-1067, Romano,M.F.,et al, 2023
Lentiviral Haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access
Lancet 399:372-383, Fumagalli, F.,et al, 2022
Migraine
NEJM 383:1866-1876, Ashina, M., 2020
Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019
Muscular Dystrophies
Lancet 394:2025-2038, Mercuri, E.,et al, 2019
DAWN: Thrombectomy Effective Up to 24 Hours after Stroke
Medscape May, Hughes, S., 2017
CGRP - The Next Frontier for Migraine
NEJM 377:2190-2191, Hershey, A.D., 2017
A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke
NEJM 372:11-20,78, Berkhemer, O.A.,et al, 2015
Endovascular Therapy for Ischemic Stroke with Perfusion-Imaging Selection
NEJM 372:1009-1018, Campbell, B.C.V.,et al, 2015
Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke
NEJM 372:1019-1030, Goyal, M.,et al, 2015
Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke
NEJM 372:DOI:10.1056/NEJMoa1415061, DOI:10.1056 NEJM e1503217, Saver, J.L.,et al, 2015
Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke
NEJM 372:DOI:10.1056 NEJMoa1503780, DOI:1056NEJM e1503217, Jovin, T.G.,et al, 2015
Efficacy of Idebenone on Respiratory Function in Patients with Duchenne Muscular Dystrophy not using Glucocorticoids (DELOS): A Double-Blind Randomised Placebo-Controlled Phase 3 Trial
Lancet 385:1748-1757,1704, Buyse, G.M.,et al, 2015
Newer Agents in the Treatment of Multiple Sclerosis
Neurologist 19:104-117, Pawate, S. & Bagnato F., 2015
Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke
NEJM 372:2285-2295,2347, Saver, J.L.,et al, 2015
Thrombectomy within 8 hours after Symptom Onset in Ischemic Stroke
NEJM 372:2296-2306,2347, Jovin, T.G.,et al, 2015
Maintenance Therapy with Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma
JAMA 314:2535-2543,2511, Stupp, R.,et al, 2015
Evidence-Based Treatments for Adults with Migraine
Pain Reser Treat 2015:DOI:10.1155/2015/629382, Gooriah, R.,et al, 2015
Hypoglossal-Nerve Stimulation for Obstructive Sleep Apnea
NEJM 370:170-171, Malhotra, A., 2014
Mechanical Thrombectomy in Severe Acute Stroke: Preliminary Results of the Solitaire Stent
JNNP 83:117-118, Mpotsaris,A.,et al, 2012
Solitaire Flow Restoration Device Versus the Merci Retriever in Patients with Acute Ischaemic Stroke (SWIFT): a Randomised, Parallel-Group, Non-Inferiority Trial
Lancet 380:1241-1249,1208, Saver, J.L.,et al, 2012
Trevo Versus Merci Retrievers for Thrombectomy Revascularisation of Large Vessel Occlusions in Acute Ischaemic Stroke (TREVO 2): A Randomised Trial
Lancet 380:1231-1240,1208, Nogueira, R.G.,et al, 2012
Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation
Stroke 43:3442-3453, Furie, K.,et al, 2012
Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Effect of Laquinimod on MRI-Monitored Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IIb Study
Lancet 371:2085-2092,2059, Comi,G.,etc., 2008
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008
Clinical Update:Diagnosis and Treatment of Essential Tremor
Lancet 369:1152-1154, Benito-Leon,J&Louis,E.D., 2007
Postmarketing Modifications in the Safety Labeling of the New Antiepileptics
Neurol 68:1536-1537, Buck,M.L.,et al, 2007
Safety and Tolerability of Gene Therapy With an Adeno-Associated Virus (AAV) Borne GAD gene for Parkinsons Disease: An Open Label, Phase I Trial
Lancet 369:2097-2105,2056, Kaplitt,M.G.,et al, 2007
Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
Adult Epilepsy
Lancet 367:1087-1100, Duncan,J.S.,et al, 2006
Magnetic Resonance Imaging of the Fetal Brain and Spine: An Increasingly Important Tool in Prenatal Diagnosis, Part 1
AJNR 27:1604-1611, Glenn,O.A. &Barkovich,A.J., 2006
Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
NEJM 352: 777-785, 828, Mayer, S.A., et al, 2005
Ximelagatran--Promises and Concerns
JAMA 293:736-739, Gurewich,V., 2005
The New Antiepileptic Drugs, Scientific Review
JAMA 291:605-614, LaRoche,S.M.&Helmers,S.L., 2004
Management of Epilepsy in Adolescents and Adults
Lancet 356:323-329, Brodie,M.J. & French,J.A., 2000
Medical Management of Epilepsy in Adults
Neurol 51:S15-S20, Mattson,R.H., 1999
Clopidogrel for Reduction of Atherosclerotic Events
The Medical Letter 40:59-60, , 1998
HIV-Protease Inhibitors
NEJM 338:1281-1292, Flexner,C., 1998
New Antiepileptic Drugs
Arch Neurol 55:1181-1183, Bourgeois,B.F.D., 1998
Parkinson's Disease
NEJM 339:1044-1053,1130-1143, Lang,A.E.&Lozano,A.M., 1998
Parenteral Fosphenytoin:Efficacy and Economic Considerations
The Neurologist 4:S30-S34, Ramsay,R.E.&Wilder,B.J., 1998
New Antiepileptic Drugs
NEJM 334:1583-1590, Dichter,M.A.&Brodie,M.J., 1996